Segment Wealth Management LLC Buys 2,631 Shares of Danaher Corporation (NYSE:DHR)

Segment Wealth Management LLC boosted its position in shares of Danaher Corporation (NYSE:DHR - Free Report) by 4.3% during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 64,533 shares of the conglomerate's stock after buying an additional 2,631 shares during the period. Segment Wealth Management LLC's holdings in Danaher were worth $13,229,000 at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of the company. Heck Capital Advisors LLC bought a new position in shares of Danaher in the 4th quarter valued at $27,000. Strategic Financial Concepts LLC acquired a new position in Danaher during the fourth quarter worth about $31,000. Rialto Wealth Management LLC bought a new position in shares of Danaher in the fourth quarter worth about $34,000. Hurley Capital LLC acquired a new stake in shares of Danaher in the 4th quarter valued at approximately $34,000. Finally, Dunhill Financial LLC grew its holdings in shares of Danaher by 68.4% during the 1st quarter. Dunhill Financial LLC now owns 165 shares of the conglomerate's stock valued at $34,000 after purchasing an additional 67 shares during the last quarter. 79.05% of the stock is owned by institutional investors.

Danaher Stock Performance

Shares of DHR opened at $194.36 on Friday. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.05 and a current ratio of 1.43. The stock has a market capitalization of $139.10 billion, a price-to-earnings ratio of 37.74, a price-to-earnings-growth ratio of 2.73 and a beta of 0.77. Danaher Corporation has a 52-week low of $171.00 and a 52-week high of $281.70. The stock's 50-day simple moving average is $193.74 and its 200 day simple moving average is $210.00.

Danaher (NYSE:DHR - Get Free Report) last announced its quarterly earnings results on Tuesday, April 22nd. The conglomerate reported $1.88 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.62 by $0.26. The firm had revenue of $5.74 billion for the quarter, compared to the consensus estimate of $5.58 billion. Danaher had a net margin of 15.81% and a return on equity of 10.80%. Research analysts forecast that Danaher Corporation will post 7.63 EPS for the current fiscal year.

Danaher Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, July 25th. Investors of record on Friday, June 27th will be paid a dividend of $0.32 per share. This represents a $1.28 annualized dividend and a yield of 0.66%. Danaher's dividend payout ratio is 24.85%.

Insider Buying and Selling

In other Danaher news, Chairman Steven M. Rales sold 1,250,000 shares of the company's stock in a transaction that occurred on Monday, May 12th. The stock was sold at an average price of $196.74, for a total value of $245,925,000.00. Following the completion of the sale, the chairman now owns 3,105,808 shares of the company's stock, valued at $611,036,665.92. This represents a 28.70% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Christopher Paul Riley sold 15,805 shares of Danaher stock in a transaction that occurred on Wednesday, April 30th. The stock was sold at an average price of $198.00, for a total transaction of $3,129,390.00. Following the transaction, the executive vice president now directly owns 15,179 shares in the company, valued at $3,005,442. This trade represents a 51.01% decrease in their ownership of the stock. The disclosure for this sale can be found here. 11.10% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

Several equities analysts recently commented on DHR shares. Barclays increased their price objective on shares of Danaher from $205.00 to $215.00 and gave the company an "overweight" rating in a research note on Tuesday, April 22nd. Evercore ISI cut their price target on shares of Danaher from $240.00 to $230.00 and set an "outperform" rating on the stock in a report on Tuesday, April 22nd. Wells Fargo & Company reduced their price objective on shares of Danaher from $240.00 to $210.00 and set an "equal weight" rating on the stock in a research note on Wednesday, April 23rd. Leerink Partners upped their price target on Danaher from $225.00 to $230.00 and gave the company an "outperform" rating in a research report on Wednesday, April 23rd. Finally, Wolfe Research dropped their price target on Danaher from $275.00 to $220.00 and set an "outperform" rating on the stock in a research note on Monday, April 7th. Five equities research analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $248.17.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.